Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
transplant
Pharma
Orca Bio takes commercial leap with FDA approval for Tregzi
Orca Bio is charging the WAC of $428,000 for Tregzi, a novel regulatory T cell-based therapy for blood cancer patients requiring transplants.
Angus Liu
Jul 1, 2026 12:14am
FDA delays decision on Orca Bio’s cell therapy for blood cancers
Apr 1, 2026 8:00am
FDA signs off on Omeros' stem cell transplant drug Yartemlea
Dec 26, 2025 12:46pm
Hansa eyes FDA filing after ph. 3 win for kidney transplant med
Sep 25, 2025 12:37pm
AZ touts Ultomiris results in post-transplant complication trial
Jun 16, 2025 10:32am
BMS's Orencia wins FDA nod for prevention of GVHD
Dec 15, 2021 3:25pm
